Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV

Journal article


Publication Details

Author(s): Saussele S, Hehlmann R, Fabarius A, Jeromin S, Proetel U, Rinaldetti S, Kohlbrenner K, Einsele H, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Leibundgut EO, Heim D, Krause S, Hofmann WK, Hasford J, Hasford J, Pfirrmann M, Mueller MC, Hochhaus A, Lauseker M, Lauseker M
Journal: Leukemia
Publication year: 2018
Volume: 32
Journal issue: 5
Pages range: 1222-1228
ISSN: 0887-6924


Abstract

Major molecular remission (MMR) is an important therapy goal in chronic myeloid leukemia (CML). So far, MMR is not a failure criterion according to ELN management recommendation leading to uncertainties when to change therapy in CML patients not reaching MMR after 12 months. At monthly landmarks, for different molecular remission status Hazard ratios (HR) were estimated for patients registered to CML study IV who were divided in a learning and a validation sample. The minimum HR for MMR was found at 2.5 years with 0.28 (compared to patients without remission). In the validation sample, a significant advantage for progression-free survival (PFS) for patients in MMR could be detected (p-value 0.007). The optimal time to predict PFS in patients with MMR could be validated in an independent sample at 2.5 years. With our model we provide a suggestion when to define lack of MMR as therapy failure and thus treatment change should be considered. The optimal response time for 1% BCR-ABL at about 12-15 months was confirmed and for deep molecular remission no specific time point was detected. Nevertheless, it was demonstrated that the earlier the MMR is achieved the higher is the chance to attain deep molecular response later.


FAU Authors / FAU Editors

Krause, Stefan Prof. Dr.
Medizinische Klinik 5 - Hämatologie und Internistische Onkologie


External institutions
Inselspital Bern
Klinikum Nürnberg
Ludwig-Maximilians-Universität (LMU)
MLL Münchner Leukämielabor GmbH
Philipps-Universität Marburg
Ruprecht-Karls-Universität Heidelberg
Universitätsklinikum des Saarlandes
Universitätsklinikum Freiburg
Universitätsklinikum Jena
Universitätsklinikum Schleswig-Holstein (UKSH)
Universitätsklinikum Tübingen
Universitätsklinikum Ulm
Universitätsklinikum Würzburg
Universitätsspital Basel


How to cite

APA:
Saussele, S., Hehlmann, R., Fabarius, A., Jeromin, S., Proetel, U., Rinaldetti, S.,... Lauseker, M. (2018). Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV. Leukemia, 32(5), 1222-1228. https://dx.doi.org/10.1038/s41375-018-0055-7

MLA:
Saussele, Susanne, et al. "Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV." Leukemia 32.5 (2018): 1222-1228.

BibTeX: 

Last updated on 2019-11-01 at 20:08